ArrayPatch raises €3.2 million to advance microneedle therapeutics in Ireland
Irish biotech firm ArrayPatch has closed an oversubscribed €3.2 million seed financing round, securing an additional €1.6 million in its second close to advance its microneedle therapeutic platform. The funding, which includes new investment from WakeUp Capital, Spark Venture Funding, and Dr. Mark Ledwidge, will accelerate development of its DerMap™ dissolving microneedle patch technology toward first-in-human studies. Initial focus areas include GLP-DerMap™ for obesity and diabetes, and VIS-DerMap™ for basal cell carcinoma. ArrayPatch's DerMap™ platform is unique in that microneedles are made entirely from the medicine itself, eliminating polymers and enabling higher drug loading. The company, spun out from University College Cork, also targets nail fungal infections and has secured support from Enterprise Ireland and other private investors.